Literature DB >> 35100907

De novo brain AVM following radiotherapy for cerebral cavernous malformation in a child: A 15-year clinical course.

Stavros Matsoukas1, Devin V Bageac1, Reade DeLeacy1, Alejandro Berenstein1, Johanna T Fifi1.   

Abstract

Multiple de novo brain arteriovenous malformations (bAVM) have been reported in the literature, raising questions about the contended purely congenital nature of these lesions. We present the 15-year course of a pediatric patient, who initially presented at age 5 with a thalamic cavernous malformation and was treated with radiosurgery, and then subsequently developed a thalamic de novo bAVM immediately adjacent to the initial lesion location, discovered 2 years later. Treatment of the bAVM entailed two transarterial embolizations and one radiosurgery session which ultimately led to complete angiographic resolution. Finally, this patient's course was complicated by intraparenchymal hemorrhage and acute obstructive hydrocephalus, and further imaging revealed two newly formed cavernous malformations, also associated with the initial lesion's location, that have remained stable since their formation. This case likely represents the second-hit model for the formation of vascular malformations, as sparsely supported by the current literature. According to this, genetically aberrant, yet quiescent, brain areas might promote the de novo formation of vascular malformations after brain injury, including radiation.

Entities:  

Keywords:  (MeSH): arteriovenous malformation; de novo; familial cerebral cavernous malformation

Mesh:

Year:  2022        PMID: 35100907      PMCID: PMC9437502          DOI: 10.1177/19714009211059115

Source DB:  PubMed          Journal:  Neuroradiol J        ISSN: 1971-4009


  15 in total

1.  Case report of a de novo brainstem arteriovenous malformation in an 18-year-old male and review of the literature.

Authors:  Kent J Kilbourn; Gary Spiegel; Brendan D Killory; Inam Kureshi
Journal:  Neurosurg Rev       Date:  2014-07-04       Impact factor: 3.042

2.  Brain arteriovenous malformation pathogenesis: a response-to-injury paradigm.

Authors:  Helen Kim; Hua Su; Shantel Weinsheimer; Ludmila Pawlikowska; William L Young
Journal:  Acta Neurochir Suppl       Date:  2011

Review 3.  Symptomatic developmental venous anomalies.

Authors:  Lorenzo Rinaldo; Giuseppe Lanzino; Kelly D Flemming; Timo Krings; Waleed Brinjikji
Journal:  Acta Neurochir (Wien)       Date:  2020-01-11       Impact factor: 2.216

4.  Expression of structural proteins and angiogenic factors in cerebrovascular anomalies.

Authors:  T Kiliç; M N Pamir; S Küllü; F Eren; M M Ozek; P M Black
Journal:  Neurosurgery       Date:  2000-05       Impact factor: 4.654

5.  Fatty acid binding protein 4 expression in cerebral vascular malformations: implications for vascular remodelling.

Authors:  Sule Cataltepe; Meltem Cevik Arikan; Xiaoliang Liang; Thomas W Smith; Oguz Cataltepe
Journal:  Neuropathol Appl Neurobiol       Date:  2015-04-30       Impact factor: 8.090

6.  Review of de novo cerebral arteriovenous malformation: haemorrhage risk, treatment approaches and outcomes.

Authors:  Xianli Lv; Guihuai Wang
Journal:  Neuroradiol J       Date:  2018-02-22

Review 7.  De novo intracerebral arteriovenous malformations and a review of the theories of their formation.

Authors:  A Dalton; G Dobson; M Prasad; N Mukerji
Journal:  Br J Neurosurg       Date:  2018-06-06       Impact factor: 1.596

8.  Real-time imaging of de novo arteriovenous malformation in a mouse model of hereditary hemorrhagic telangiectasia.

Authors:  Sung Ok Park; Mamta Wankhede; Young Jae Lee; Eun-Jung Choi; Naime Fliess; Se-Woon Choe; Seh-Hoon Oh; Glenn Walter; Mohan K Raizada; Brian S Sorg; S Paul Oh
Journal:  J Clin Invest       Date:  2009-10-01       Impact factor: 14.808

9.  Endothelial Notch signaling is upregulated in human brain arteriovenous malformations and a mouse model of the disease.

Authors:  Patrick A Murphy; Gloria Lu; Steven Shiah; Andrew W Bollen; Rong A Wang
Journal:  Lab Invest       Date:  2009-06-22       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.